Sep 4, 2019

Multiple Myeloma Update — Part 3: Our interview with Dr Shah highlights the following topics as well as cases from her practice:

• Recently approved and novel antibodies in the treatment of MM (00:00)
• Use and tolerability of elotuzumab/pomalidomide/dexamethasone for patients with R/R MM (01:52)
• Activity, tolerability and ongoing investigation of the anti-CD38 antibodies daratumumab and isatuximab (04:50)
• Biologic rationale for targeting BCMA; near universal expression of BCMA on MM cells (08:58)
• Exploration of consolidation anti-BCMA CAR T-cell therapy after transplant (11:20)
• Outcomes and frequency and severity of toxicities observed with BCMA-directed CAR T-cell platforms versus those targeting CD19 (13:37)
• Case: A man in his early 60s with R/R MM receives anti-BCMA CAR T-cell therapy on a clinical trial (16:18)
• Clinical manifestations and management of cytokine release syndrome associated with anti-BCMA CAR T-cell therapy (19:49)
• Correlation between toxicity and benefit with BCMA-directed CAR T-cell therapy (22:45)
• Challenges to entering patients on CAR T-cell therapy trials (25:51)
• DREAMM-1 trial: Efficacy and safety of the investigational BCMA-directed antibody-drug conjugate GSK2857916 in patients with heavily pretreated MM (28:46)
• Use of a bispecific T-cell engager to target BCMA and CD3 in patients with MM; early efficacy and safety of AMG 420 (31:33)
• Case: A man in his early 80s with newly diagnosed MM receives CyBorD (cyclophosphamide/bortezomib/dexamethasone) followed by maintenance lenalidomide (34:55)
• Phase III MAIA trial: Efficacy and tolerability of lenalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM who are not candidates for ASCT (37:11)

CME information and select publications